US companies seeking for listings on Hong Kong exchange

In February 2018, the Hong Kong Exchanges and Clearing Limited (“HKEX”) issued a consultation paper seeking public feedback on its proposal to expand the existing listing regime to allow the listing of:

  • Biotech issuers which are pre-profit/pre-revenue; 
  • Companies from emerging and innovative sectors that have weighted voting rights structures; and
  • Companies already listed on the NYSE or Nasdaq to seek for secondary listing. 

The proposed changes are expected to attract high potential biotech companies as well as already listed companies from around the world to seek for a listing in Hong Kong.

What are some of the topics that US based companies should pay special attention at when considering a Hong Kong listing? 

Contact us

Kennedy Liu

Head of Capital Markets and Accounting Advisory Services , PwC Hong Kong

Tel: +[852] 2289 1881

Edmond Chan

Capital Markets Services Co-Head, PwC Hong Kong

Tel: +[852] 2289 1128

Pauline Leung

Partner, PwC Hong Kong

Tel: +[852] 2289 1809

Follow us